| Chairman |
|
Zhu Zhongyuan |
| Business Nature |
| 醫療保健 (Health Care) |
| Board Members |
Chairman & Chief Executive Officer: Zhu Zhongyuan
Executive Director: Zhang Shaoren, Si Wen
Non-executive Director: Cai Zhiyang, Yu Tao
Independent Non-executive Director: Xie Dong, Gao Fengyong, Chuai Shuyin.
|
| Principle Business |
|
The Group is a global clinical-stage biopharmaceutical company discovering, developing next generation Antibody-Drug Conjugate therapeutics in the PRC and the US. |
| Related Indexes | | Hang Seng Composite Index | Hang Seng Biotech Index | | Hang Seng Healthcare Index | Hang Seng Composite MidCap Index | | Hang Seng Healthcare Industry Index |
|
| Major Shareholders |
| Shi Yi | 11,652,921 | 12.93% | 2026/01/31 | | Zhu Zhongyuan | 6,500,000 | 7.38% | 2025/06/30 | | Shanghai Yingjia Enterprise Management Partnership (Limited Partnership) | 6,387,649 | 7.48% | 2025/04/15 | | King Star Med LP | 5,279,554 | 5.98% | 2025/11/28 |
|
|
|
|
|